On Eve of Annual Update Conference, Commerce Announces Proposed Rule To Address Future Controls Over Items Removed From USML
Client Alert | 1 min read | 07.15.11
Today, the Bureau of Industry & Security (BIS) published a proposed rule, 76 Fed. Reg. 41958, which would create a structured approach for addressing items to be removed from the U.S. Munitions List where continued control under the EAR is necessary. The extensive revisions are discussed under four general topics:
- Creation of a new "600 series" of numbers within each Category and Group on the Commerce Control List (CCL) where items to be released from control under the USML that do not otherwise fit within an existing ECCN controlled for more than AT reasons. This series of ECCNs is considered necessary to ensure adequate national security control over many of the items to be removed from the USML as well as to comply with certain multilateral commitments like the Wassenaar Military List.
- Creation of ECCN 0Y521 as an equivalent to Category XXI (Miscellaneous Items) of the USML to capture and provide temporary control over newly emerging products and technology not otherwise covered under the CCL while the government considers the appropriate control. It is envisioned this temporary control will last no longer than 1 year.
- Creation of a single definition (except for MTCR) of "specially designed" even though a goal of the "positive list" reform was to eliminate as much as possible control over items that cannot be specifically identified at least by defined functional and operational characteristics. The term has become ubiquitous, however, appearing 264 times in the CCL and in multilateral regimes (no need to wonder how it got there) such that BIS considers it impractical to excise it from the export control vocabulary.
- Other changes designed to assist the structural alignment of the USML and CCL to foster the goal of reaching a single positive list.
The proposed regulations have lofty ambitions but will require significant study and testing to determine how close they come to achieving those goals. So in the meantime, get out your pens and pencils and prepare your questions for the Update Conference next week – and watch this space for additional analysis and comment.
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection

